In a report released today, Brian Cheng from J.P. Morgan maintained a Buy rating on PTC Therapeutics, with a price target of $68.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brian Cheng has given his Buy rating due to a combination of factors that highlight the potential growth and strong market positioning of PTC Therapeutics. The recent launch of Sephience for PKU in the U.S. is a significant development, with early indications showing strong uptake at major academic institutions and minimal resistance from payors. This positive reception, coupled with favorable prescriber experiences and quick prescription fulfillment, suggests a promising trajectory for Sephience’s market penetration.
Moreover, Cheng’s analysis points to a robust demand for Sephience, supported by channel checks and management’s optimistic outlook. The company’s strategic positioning is further bolstered by additional growth opportunities from other products like vatiquinone and translarna, as well as a solid financial backing from partnerships. The sum-of-the-parts analysis indicates substantial upside potential, with a December 2026 price target of $68, reflecting confidence in the company’s diversified revenue streams and strategic initiatives.
In another report released on October 8, RBC Capital also maintained a Buy rating on the stock with a $70.00 price target.
Based on the recent corporate insider activity of 66 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTCT in relation to earlier this year.